Success Metrics

Clinical Success Rate
95.8%

Based on 46 completed trials

Completion Rate
96%(46/48)
Active Trials
6(9%)
Results Posted
28%(13 trials)
Terminated
2(3%)

Phase Distribution

Ph phase_3
13
19%
Ph phase_2
17
25%
Ph phase_4
16
24%
Ph phase_1
2
3%
Ph not_applicable
20
29%

Phase Distribution

2

Early Stage

17

Mid Stage

29

Late Stage

Phase Distribution68 total trials
Phase 1Safety & dosage
2(2.9%)
Phase 2Efficacy & side effects
17(25.0%)
Phase 3Large-scale testing
13(19.1%)
Phase 4Post-market surveillance
16(23.5%)
N/ANon-phased studies
20(29.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.6%

46 of 55 finished

Non-Completion Rate

16.4%

9 ended early

Currently Active

6

trials recruiting

Total Trials

68

all time

Status Distribution
Active(8)
Completed(46)
Terminated(9)
Other(5)

Detailed Status

Completed46
Withdrawn7
unknown5
Recruiting4
Active, not recruiting2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
68
Active
6
Success Rate
95.8%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (2.9%)
Phase 217 (25.0%)
Phase 313 (19.1%)
Phase 416 (23.5%)
N/A20 (29.4%)

Trials by Status

unknown57%
withdrawn710%
completed4668%
active_not_recruiting23%
not_yet_recruiting23%
recruiting46%
terminated23%

Recent Activity

Clinical Trials (68)

Showing 20 of 68 trialsScroll for more
NCT03172975Phase 2

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Completed
NCT04311671Phase 3

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Completed
NCT05949190Not Applicable

Improving Cognition and Gestational Duration With Targeted Nutrition

Active Not Recruiting
NCT04410406Phase 3

Moxidectin for LF, Cote d'Ivoire (DOLF)

Completed
NCT03014167Phase 3

Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

Completed
NCT05124691Phase 2

Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

Terminated
NCT07074444Phase 4

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Recruiting
NCT04713787Phase 2

A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults

Recruiting
NCT06483880Not Applicable

The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

Recruiting
NCT06631612Phase 4

Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia

Active Not Recruiting
NCT06265870Not Applicable

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia

Recruiting
NCT04913610Phase 2

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Terminated
NCT06376396Phase 4

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Not Yet Recruiting
NCT03527732Phase 2

Efficacy and Safety of IVM/ALB Co-administration

Completed
NCT03435718Phase 2

Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

Not Yet Recruiting
NCT03527745Phase 2

Albendazole Dose Finding and Pharmacokinetics in Children and Adults

Completed
NCT00755560Phase 3

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

Unknown
NCT05354258Not Applicable

Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children

Unknown
NCT05453045Not Applicable

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Unknown
NCT03474276Phase 3

Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old

Completed

Drug Details

Intervention Type
DRUG
Total Trials
68